Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial

Fibrinogen concentrate is the preferred choice for fibrinogen replacement in congenital fibrinogen deficiency. This study investigated hemostatic efficacy of a new plasma‐derived, double virus‐inactivated (using two dedicated virus inactivation/elimination steps) human fibrinogen concentrate for on‐demand treatment of bleeding episodes (BEs) and surgical prophylaxis.

• Publication year

  2018

• Venue

  Transfusion

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/trf.14421PMID 29194665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of a VWF/FVIII concentrate (wilate®) in inherited von Willebrand disease patients undergoing surgical procedures

  2017cited by this paper
• Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: Final Analysis

  2015cited by this paper
• Cryoprecipitate therapy

  2014cited by this paper
• Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data

  2014cited by this paper
• Use of objective efficacy criteria for evaluation of von willebrand factor/factor VIII concentrates

  2012cited by this paper
• Rare bleeding disorders

  2012cited by this paper
• Fibrinogen replacement therapy: a critical review of the literature.

  2012cited by this paper
• Fibrinogen replacement therapy for congenital fibrinogen deficiency

  2011cited by this paper
• Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia.

  2010cited by this paper
• Efficacy and safety of highly purified, doubly virus‐inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score

  2010cited by this paper
• A critical evaluation of cryoprecipitate for replacement of fibrinogen

  2010cited by this paper
• Treatment and prevention of acute bleedings in von Willebrand disease – efficacy and safety of Wilate®, a new generation von Willebrand factor/factor VIII concentrate

  2009cited by this paper
• Pharmacokinetics and safety of fibrinogen concentrate

  2009cited by this paper
• Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency

  2008cited by this paper
• Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders

  2008cited by this paper
• Rare inherited disorders of fibrinogen

  2008cited by this paper
• Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

  2007cited by this paper
• Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia

  2006cited by this paper
• Rare bleeding disorders

  2006cited by this paper
• Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency.

  2005cited by this paper
• The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation

  2004cited by this paper
• Recessively inherited coagulation disorders.

  2004cited by this paper
• Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias

  2004cited by this paper
• Guidelines for the use of fresh‐frozen plasma, cryoprecipitate and cryosupernatant

  2004cited by this paper
• Rare coagulation deficiencies

  2002cited by this paper
• The Structure and Biological Features of Fibrinogen and Fibrin

  2001cited by this paper
• Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia

  1999cited by this paper
• Pharmacokinetics, efficacy and safety of Humate‐P® in von Willebrand disease

  1998cited by this paper
• Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease.

  1998cited by this paper
• Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Treatment of Congenital Fibrinogen Deficiency: Overview and Recent Findings

  year unknowncited by this paper

• Efficacy and safety of prophylaxis and treatment of bleeding events with a novel fibrinogen concentrate from human plasma in patients with congenital fibrinogen deficiency.

  2026cites this paper
• Viscoelastic testing in patients with very rare bleeding disorders of secondary hemostasis, a scoping review.

  2025cites this paper
• How I treat quantitative fibrinogen disorders.

  2024cites this paper
• One Hundred Years of Congenital Fibrinogen Disorders.

  2022cites this paper
• Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective

  2022cites this paper
• The role of fibrinogen in traumatic brain injury: from molecular pathological mechanisms to clinical management

  2022cites this paper
• Impact of fibrinogen infusion on thrombin generation and fibrin clot structure in patients with inherited afibrinogenemia.

  2022cites this paper
• Clinical Uses of Blood Components

  2021cites this paper
• Hemostatic Agents and Blood Components Used to Stop Bleeding

  2021cites this paper
• TEG® and ROTEM® Traces: Clinical Applications of Viscoelastic Coagulation Monitoring in Neonatal Intensive Care Unit

  2021cites this paper
• Clinical phenotype, fibrinogen supplementation and health-related quality of life in patients with afibrinogenemia.

  2021cites this paper
• Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management.

  2020cites this paper
• Perioperative management of a severe congenital hypofibrinogenemia with thrombotic phenotype.

  2020cites this paper
• Manifestations and Treatment of Congenital Fibrinogen Deficiency

  2020cites this paper
• Pulmonary Thromboendarterectomy Requiring Cardiopulmonary Bypass and Deep Hypothermic Circulatory Arrest in a Patient With Congenital Afibrinogenemia.

  2020cites this paper
• Bleeding characteristics and management of minor surgeries in rare bleeding disorders: report from a Turkish Pediatric Hematology Center.

  2020cites this paper
• Impact of fibrinogen level on the prognosis of patients with traumatic brain injury: a single-center analysis of 2570 patients

  2020cites this paper
• Fibrinogen concentrates in hereditary fibrinogen disorders: Past, present and future

  2019cites this paper
• Blood, blood components, plasma, and plasma products

  2019cites this paper
• Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients

  2019cites this paper
• Clinical pharmacology, efficacy and safety study of a triple‐secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency

  2019cites this paper
• In Vitro Anticoagulant Activity of Mikania laevigata: Deepening the Study of the Possible Interaction Between Guaco and Anticoagulants.

  2019cites this paper
• Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee

  2019cites this paper
• Critical developments of 2017: a review of the literature from selected topics in transfusion. A committee report from the AABB Clinical Transfusion Medicine Committee

  2018cites this paper